{"contentid": 488093, "importid": NaN, "name": "Pivotal failure dents promise of checkpoint blocker complement", "introduction": "USA-based oncology specialist Idera Pharmaceuticals has been dealt a severe blow by a negative result from the pivotal ILLUMINATE-301 trial.", "content": "<p>USA-based oncology specialist Idera Pharmaceuticals (Nasdaq: IDRA) has been dealt a severe blow by a negative result from the pivotal ILLUMINATE-301 trial.</p>\n<p>The firm is testing its investigational immunotherapy tilsotolimod, in combination with Bristol Myers Squibb&rsquo;s (NYSE: BMY) Yervoy (ipilimumab), in refractory advanced melanoma.</p>\n<p>Spying a high level of unmet medical need in anti-PD1 refractory patients, Idera estimates that peak US sales for the product could reach $500 million in this indication, if approved.</p>\n<p>The firm, which is hoping to make the synthetic Toll-like receptor 9 agonist its first approved medicine, saw its shares fall back over 60% in pre-market trading on Friday.</p>\n<h2>Development setback</h2>\n<p>Results show ILLUMINATE-301, which pits the combo against treatment with Yervoy alone, did not meet its primary endpoint of objective response rate (ORR).</p>\n<p>Idera said it was mulling whether to continue the trial toward its overall survival (OS) endpoint, and that it would evaluate the full data set when it is available.</p>\n<p>The company also plans to continue its ILLUMINATE-206 Phase II study of tilsotolimod in a triplet combination with both Yervoy and Opdivo (nivolumab), in colorectal cancer.</p>\n<p>Chief executive Vincent Milano said: &ldquo;We are surprised and disappointed that the response data from ILLUMINATE-301 do not lead us to an accelerated path to a new and much-needed treatment option for these patients.&rdquo;</p>\n<p>He added: &ldquo;Despite today&rsquo;s news, we are continuing to explore tilsotolimod via our ongoing ILLUMINATE-206 study in order to understand its potential to lead to better outcomes for patients with MSS-CRC.&rdquo;</p>\n<p>Tilsotolimod has received both Fast Track designation and Orphan Drug designation from the US Food and Drug Administration.</p>", "date": "2021-03-19 14:08:00", "meta_title": NaN, "meta_keywords": "ILLUMINATE-, pivotal, Idera, trial, checkpoint, blocker, complement, promise, dents, tilsotolimod, failure, USA-based, oncology, specialist, Pharmaceutical", "meta_description": "USA-based oncology specialist Idera Pharmaceuticals (Nasdaq: IDRA) has been dealt a severe blow by a negative result from the pivotal ILLUMINATE-301 trial.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-19 14:07:48", "updated": "2021-03-19 14:34:06", "access": NaN, "url": "https://www.thepharmaletter.com/article/pivotal-failure-dents-promise-of-checkpoint-blocker-complement", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_biomarker_biotech_test_big.jpg", "image2id": "2020_biomarker_biotech_test_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Drug Trial, Research", "geography_tag": "USA", "company_tag": "Idera Pharmaceuticals", "drug_tag": "tilsotolimod", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-19 14:08:00"}